Kumar P P, Patil A A, Leibrock L G, Chu W K, Syh J, McCaul G F, Reeves M A
Division of Radiation Oncology, University of Nebraska Medical Center, Omaha.
Neurosurgery. 1991 Nov;29(5):676-80.
Thirteen patients with intracranial meningiomas of the skull base were treated with one or more high-activity iodine-125 seeds. In 11 patients, the seeds were implanted stereotactically under local anesthesia. A minimum dose of 100 to 500 Gy was delivered to the tumor at a dose rate of 5 to 25 cGy/h. Indications for this procedure included recurrence after initial surgery or as the primary modality of treatment in patients who were not candidates for surgery. All 13 patients are alive at a median follow-up of 15 months. Nine of 11 patients (82%) without calcification in their meningiomas achieved complete response. The remaining 4 patients-2 with calcification and 2 without--achieved partial response. No early or late complications were observed. We conclude from our experience that both recurrent and primary meningiomas of the skull base can be treated effectively with permanent iodine-125 brachytherapy.
13例颅底颅内脑膜瘤患者接受了一粒或多粒高活性碘-125粒子治疗。11例患者在局部麻醉下通过立体定向植入粒子。以5至25 cGy/h的剂量率向肿瘤输送的最小剂量为100至500 Gy。该手术的适应症包括初次手术后复发或作为不适合手术患者的主要治疗方式。13例患者均存活，中位随访时间为15个月。11例脑膜瘤无钙化的患者中有9例（82%）达到完全缓解。其余4例患者——2例有钙化，2例无钙化——达到部分缓解。未观察到早期或晚期并发症。根据我们的经验，我们得出结论，颅底复发性和原发性脑膜瘤均可通过永久性碘-125近距离放射治疗得到有效治疗。
